BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel

Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to continue developing a microparticle therapy for treating cerebral amyloid angiopathy (CAA), a condition responsible for inflicting significant neurologic damage and afflicting greater than 85% of Alzheimer’s patients. The grant builds on Karamedica’s nose-to-brain delivery system that was validated

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy Designation to Cyprium Therapeutics (“Cyprium”) for CUTX-101, a potential treatment for Menkes disease. Often lethal

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the presentation of RECELL® System data recently presented at the Northeast Regional Burn Conference and Southern Regional Burn Conference of the American Burn Association.

Applied Health Analytics, provider of analytics, technology and services to hospitals and health systems that support population health management, has released an update to its bMetrix™ Biometric Screening application to include vaccine injection management, member communication and reporting capabilities for COVID-19 vaccinations

The GENOSYL® DS facilitates patient treatment in interhospital and intrahospital transport, and in diverse diagnostic and imaging settings, representing the broadest FDA approved label in the industry allowing use in the Acute-care Setting including MRI, Ground, Fixed Wing and Rotary Transport.

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC).

- EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms - Acquisition significantly expands AnGes’ global leadership, broad capabilities in genetic medicine as well as its pipeline and platforms NEW YORK & TEL AVIV, Israel & OSAKA, Japan--( BUSINESS WIRE )--

HORIBA Medical, a leading global diagnostic company providing solutions in chemistry, hematology and hemostasis, today announced that it has obtained U.S. Food and Drug Administration (FDA) and Health Canada clearance in North America for its next generation clinical chemistry system, the Yumizen C1200.

The combined company will improve access to health economics and outcomes research (HEOR), real world evidence (RWE) and market access services for researchers in the life sciences